Project Grant R01CA282657
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $881,647 Project Grant to Panome Bio Inc. under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant supports research to advance untargeted metabolomics approaches for biomarker discovery in colon cancer. Specifically, Panome Bio is developing novel software and analytical methods to enhance the value and impact of untargeted metabolomics by addressing...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) has awarded Emory University a Project Grant of $156,500.00 to conduct a comprehensive multi-omics investigation of the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The 2-year project, running from August 1, 2025 to July 31, 2027, aims to gain a deeper understanding of the early biological mechanisms driving cachexia, a lethal syndrome affecting up to 80% of advanced cancer patients....
- This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $1,583,640 to the University of California, San Diego (UC San Diego) from June 23, 2025 to May 31, 2028 to advance spatial metabolomics research for cancer. The project aims to develop and apply the METASPACE open-source software platform to enable data analysis and interpretation of large, complex spatial metabolomics datasets generated through imaging mass spectrometry techniques....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on "Decoding the Metabolic Routes of Purine Nucleotides in Cancer". The overarching goal is to expand the mechanistic understanding of purine synthesis pathways in tumors and identify new strategies to target purine supply mechanisms for effective cancer treatment. Key research aims include:...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $646,739.00 in funding to Cedars-Sinai Medical Center to investigate the molecular mechanisms underlying the role of hepatic stellate cells (HSCs) in promoting liver metastasis, particularly in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). The key research objectives are to: 1) examine the regulatory mechanism and functional role of extra-tumoral...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...
CREATION OF THE HUMAN CANCER METABOLOME ATLAS - PROJECT SUMMARY/ABSTRACT METABOLIC REPROGRAMMING IS A HALLMARK OF CANCER, PROMPTING MOLECULAR MECHANISMS TO PROMOTE TUMOR SURVIVAL, GROWTH, AND RESISTANCE TO TREATMENT. THERAPEUTIC TARGETING OF TUMOR METABOLISM THEREFORE IS BELIEVED TO BE A PROMISING AVENUE OF CANCER TREATMENT. TO FURTHER THE DEVELOPMENT OF METABOLISM-TARGETED CANCER THERAPY, MORE INFORMATION IS NEEDED CONCERNING THE HETEROGENEITY OF TUMOR METABOLISM AND HOW TUMOR TYPE, STAGE, AND OTHER TUMOR/PATIENT CHARACTERISTICS DETERMINE THE METABOTYPE OF TUMORS. ALTHOUGH PUBLICLY AVAILABLE RESOURCES EXIST FOR GENOMICS AND PROTEOMICS DATA, SUCH AS THE CANCER GENOME ATLAS (TCGA) AND THE HUMAN PROTEOME ATLAS (HPA), NO SUCH DATABASE EXISTS FOR THE CANCER METABOLOME. RESOURCES LIKE TCGA AND HPA HAVE BECOME CORNERSTONES OF CANCER RESEARCH, MAKING THE LACK OF A CANCER METABOLOME RESOURCE A GLARING OMISSION, PARTICULARLY SINCE METABOLOMICS IS CONSIDERED TO BE THE OMICS CLOSEST TO PHENOTYPE. WE PROPOSE TO CREATE THE HUMAN CANCER METABOLOME ATLAS (HCMA) BY COLLECTING METABOLOMICS DATA ON NUMEROUS PATIENT- DERIVED TUMORS AND MAKING AN OPEN-ACCESS RESOURCE TO THE CANCER COMMUNITY TO BETTER UNDERSTAND THE ROLE OF METABOLISM IN CANCERS. IN AIM 1,WE WILL ANALYZE A LARGE-SCALE COLLECTION (>2000) PATIENT-DERIVED XENOGRAFTS (PDXS) USING MASS SPECTROMETRY-BASED METABOLOMICS. WE WILL OBTAIN THESE PDXS FROM NCI'S PATIENT DERIVED MODEL REPOSITORY (PDMR), CHARLES RIVER LABORATORY, AND CROWN BIOSCIENCE. EACH PDX MODEL HAS ALREADY BEEN CHARACTERIZED BY RNA-SEQUENCING, WHOLE EXOME SEQUENCING, AND COMES WITH A WEALTH OF PATIENT INFORMATION/METADATA. IN AIM 2, WE WILL EVALUATE HOW METABOTYPES OF PDXS VARY BASED ON GENE EXPRESSION PATTERNS, PRESENCE OF METASTATIC DISEASE, AND SURVIVAL OUTCOMES. USING A COMBINATION OF UNIVARIATE, MULTIVARIATE, AND PATHWAY ANALYSES, WE WILL UNCOVER KEY ROLES OF CANCER METABOLISM IN THESE PROCESSES AND WHICH ASPECTS OF CANCER METABOLISM CONTRIBUTE TO HETEROGENEITY ACROSS PATIENTS. FINALLY, IN AIM 3 WE WILL CREATE A PUBLIC RESOURCE FOR THE HCMA USING THE NATIONAL METABOLOMICS DATA REPOSITORY (NMDR, ALSO KNOWN AS METABOLOMICS WORKBENCH). RAW AND PROCESSED METABOLOMICS DATA WILL BE UPLOADED TO THIS RESOURCE ALONG WITH ASSOCIATED PATIENT METADATA AND EXISTING GENETIC DATA TO FACILITATE DATA MINING AND DISCOVERY EFFORTS TO BE PERFORMED BY OUTSIDE INVESTIGATORS. EXISTING DATA ANALYSIS MODULES OF THE NMDR INCLUDING UNIVARIATE ANALYSIS, MULTIVARIATE ANALYSIS, PATHWAY ANALYSIS, AND METABOLITE CLASS ANALYSIS WILL BE INTEGRATED WITH THE HCMA TO MAKE THE METABOLOMICS DATA ACCESSIBLE AND EASILY ANALYZABLE BY OTHER INVESTIGATORS. THIS RESOURCE WILL CONTINUALLY BE BUILT UPON IN FUTURE PROPOSALS TO EXPAND THE HCMA AND PROVIDE A POWERFUL RESOURCE FOR NEW DISCOVERIES IN CANCER BIOLOGY AND THERAPEUTICS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $648.0k | 8/18/25 | ||
| Not listed | $661.8k | 8/1/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
5132778S | University Of California, San Diego | Project Grant R01CA282657 | $166.3k | 11/27/24 |